News

January 1, 2024

Neurotech Executives Jim Mazzo, Chairman and Rich Small, Chief Executive Officer to Present at Annual J.P. Morgan Healthcare Conference

December 2, 2023

Rich Small, Chief Executive Officer, Presents a Company Update at the Retina Innovation Showcase at the Ophthalmology Innovation Summit (OIS) XIII

November 2, 2023

Chief Executive Officer, Rich Small Joins the Panel Discussion “Key Ingredients of Successful Innovation” at the American Academy of Ophthalmology Eyecelerator Meeting in San Francisco on November 2, 2023

October 26, 2023

Rich Small, Chief Executive Officer presents a company update at the Retina Ocular Surgery News Disruptive Innovations Symposium in New York on October 26, 2023

September 13, 2023

Alex Gorsky Appointed to Neurotech’s Board as Lead Director

June 9, 2023

Rich Small, Chief Executive Officer Joins the Executive Panel Discussion “Innovations in the Posterior Segment” at the Octane Ophthalmology Tech Forum in Newport Beach, California on June 9, 2023

January 10, 2023

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

November 2, 2022

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

October 24, 2022

Neurotech Chief Medical Officer authors article in Ophthalmology Times

A roadmap to preserving the prime years of patients diagnosed with MacTel, was published by Ophthalmology Times and written by Thomas Aaberg, Jr., explores the progression of MacTel and the… read more

July 20, 2022

Neurotech Chief Medical Officer authors article in The Ophthalmologist

The article, A Tiny Factory: Scaffolding a solution to macular telangiectasia with encapsulated cell therapy, was published by The Ophthalmologist and written by Thomas Aaberg, Jr., explores how ECT can… read more